REDUCE-IT: Prescription EPA Cut Heart Events 25% in Statin Users

A purified prescription EPA (icosapent ethyl, 4 g/day) cut cardiovascular events by 25% in statin users with high triglycerides.

This article walks through the N Engl J Med (2019) REDUCE-IT trial in plain English: who was enrolled, what changed, what the limits are, and what it does not prove. Full citation and DOI link are below, with a PubMed record.

What the study found

REDUCE-IT was a multicenter, randomized, double-blind, placebo-controlled trial of 8,179 statin-treated patients with elevated triglycerides and either established cardiovascular disease or diabetes plus other risk factors. Participants took icosapent ethyl 4 g per day or placebo.

Over a median of 4.9 years, a primary cardiovascular event occurred in 17.2% of the icosapent ethyl group vs 22.0% on placebo (HR 0.75). Cardiovascular death was 4.3% vs 5.2% (HR 0.80). Atrial fibrillation or flutter leading to hospitalization was more common with icosapent ethyl (3.1% vs 2.1%). The trial tested prescription icosapent ethyl, not over-the-counter fish oil.

Key finding (from the study record): Primary events 17.2% vs 22.0% (HR 0.75); CV death 4.3% vs 5.2% (HR 0.80) over 4.9 years.

How the study was done

• **Design:** Multicenter double-blind placebo-controlled RCT (REDUCE-IT)
• **Who was studied:** 8,179 statin-treated patients with high triglycerides and CVD or diabetes
• **Journal / year:** N Engl J Med (2019)
• **First author:** Bhatt DL et al.
• **Dose studied:** icosapent ethyl 2 g twice daily (4 g/day total)

Patients were already on statin therapy with LDL cholesterol mostly in a controlled range, and triglycerides between 135 and 499 mg/dL at qualifying visits. Events such as heart attack, stroke, coronary revascularization, unstable angina, and cardiovascular death were tracked over years — not weeks.

What it means — and what it does not

Useful takeaway: A purified prescription EPA (icosapent ethyl, 4 g/day) cut cardiovascular events by 25% in statin users with high triglycerides.

Limits and caveats: Prescription drug (Vascepa), not OTC fish oil; mineral-oil placebo controversy; AFib hospitalization 3.1% vs 2.1%; Amarin funded.

This evidence can inform a conversation with a licensed provider. It is not a guarantee of similar results for you, and it is not a recommendation to start, stop, or change any medication on your own. Over-the-counter fish oil is not the drug studied here.

How this connects to care

AZTRT serves men in Arizona with telehealth evaluation, labs, and provider-guided plans when appropriate. Plans start at $149/month or $357/quarter and include initial labs only. Medication ships three months at a time when prescribed.

Heart risk, triglycerides, weight, and hormones often show up in the same workup. Relevant pages:

• Tirzepatide (weight loss) (branded trial drugs are not the same as compounded products, which are not FDA-approved)
• TRT overview
• Book a free consult

FAQ

What did this study actually find?

A purified prescription EPA (icosapent ethyl, 4 g/day) cut cardiovascular events by 25% in statin users with high triglycerides. The design was: Multicenter double-blind placebo-controlled RCT (REDUCE-IT). Population: 8,179 statin-treated patients with high triglycerides and CVD or diabetes.

Is this the same as fish oil from the drugstore?

No. REDUCE-IT tested prescription icosapent ethyl (Vascepa), a highly purified EPA ethyl ester at 4 g/day. Mixed OTC omega-3 supplements were not the intervention.

Does this mean I should start EPA?

No. Research informs care; it does not prescribe it. A licensed provider reviews your lipids, heart history, and other medications — including atrial fibrillation risk — before any decision. Results vary.

What are the main limits?

Prescription drug (Vascepa), not OTC fish oil; mineral-oil placebo controversy; AFib hospitalization 3.1% vs 2.1%; Amarin funded.

Keep reading

• SELECT Trial: Semaglutide and Heart Outcomes in Obesity Without Diabetes
• TRAVERSE Trial: Does TRT Raise Heart Attack Risk? What the Data Show
• Fitness vs Smoking for Longevity: Lessons From 122,007 Treadmill Tests
• The Connection Between Testosterone and Heart Health

Reference

Bhatt DL et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019. https://doi.org/10.1056/NEJMoa1812792 · PubMed 30415628.

Next step

Book a free consult with an Arizona-licensed provider. Bring your questions — including anything this study raised for you.

Plans start at $149/month or $357/quarter and include initial labs only. Medication ships three months at a time when prescribed.

Talk to a licensed provider. Results vary. Not medical advice.

Talk to a licensed provider. Results vary. Not medical advice.